Barclays Raises BeOne Medicines (NASDAQ:ONC) Price Target to $405.00

BeOne Medicines (NASDAQ:ONC) had its target price increased by Barclays from $394.00 to $405.00 in a report released on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 27.76% from the stock’s previous close.

Other equities analysts have also recently issued reports about the stock. Citizens Jmp upped their price target on shares of BeOne Medicines from $348.00 to $396.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Royal Bank Of Canada upped their target price on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research report on Thursday. Sanford C. Bernstein upgraded shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price target for the company in a research report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, January 21st. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $405.00 price objective on shares of BeOne Medicines in a report on Thursday, January 8th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $394.25.

BeOne Medicines Price Performance

Shares of ONC opened at $316.99 on Friday. The company has a current ratio of 2.39, a quick ratio of 2.17 and a debt-to-equity ratio of 0.03. The stock’s 50 day moving average is $336.81 and its two-hundred day moving average is $330.70. BeOne Medicines has a twelve month low of $196.45 and a twelve month high of $385.22. The firm has a market capitalization of $34.76 billion, a PE ratio of 125.79 and a beta of 0.52.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $1.60 by ($1.02). BeOne Medicines had a net margin of 5.37% and a return on equity of 11.10%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Research analysts anticipate that BeOne Medicines will post -5.82 earnings per share for the current year.

Insider Activity at BeOne Medicines

In related news, SVP Chan Henry Lee sold 1,660 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $349.52, for a total value of $580,203.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John Oyler sold 75,631 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $307.79, for a total value of $23,278,465.49. Following the sale, the chief executive officer owned 24,369 shares in the company, valued at approximately $7,500,534.51. This trade represents a 75.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 102,656 shares of company stock valued at $31,567,496 over the last 90 days. Insiders own 6.62% of the company’s stock.

Institutional Trading of BeOne Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA acquired a new stake in shares of BeOne Medicines during the 2nd quarter worth about $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in BeOne Medicines during the second quarter worth approximately $244,603,000. Marshall Wace LLP purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $113,190,000. Baird Financial Group Inc. acquired a new position in BeOne Medicines in the 2nd quarter valued at $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in BeOne Medicines in the 2nd quarter valued at $73,347,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Key Headlines Impacting BeOne Medicines

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Analysts raised price targets — Truist boosted its target to $412 (buy), implying ~30% upside from the cited reference price. Benzinga
• Positive Sentiment: Guggenheim raised its target to $410 (buy), signaling similar upside (~29%). Benzinga
• Positive Sentiment: Barclays raised its target to $405 and kept an overweight rating, another vote of confidence from sell‑side analysts. Benzinga
• Neutral Sentiment: Revenue beat — Q4 revenue was $1.50B vs. consensus ~$1.45B, showing top‑line strength even as other metrics disappointed. Earnings Presentation
• Neutral Sentiment: Analyst/coverage writeups and Q4 metric breakdowns are available (Zacks, Seeking Alpha, Yahoo) for investors wanting full detail on margins, ROE and segment performance. Zacks Analysis Yahoo
• Neutral Sentiment: Reported short‑interest data in the feed shows zero/NaN values and a 0.0 days‑to‑cover ratio — likely data reporting issues rather than a meaningful change in short activity.
• Negative Sentiment: Large EPS miss — Q4 EPS of $0.58 missed consensus ~$1.60 by ~$1.02, a key negative that pressured sentiment despite revenue strength. (See Q4 results commentary.)
• Negative Sentiment: Disappointing FY2026 guidance — company issued revenue guidance of ~$6.2–6.4B vs. consensus ~6.5B, which the market viewed as conservative and has weighed on the stock. Investing.com
• Negative Sentiment: Coverage/articles highlight the post‑earnings selloff and investor reassessment after the EPS miss and guidance gap. YicaiGlobal

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.